亚宝药业终止SY-009的临床研究开发工作

Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project after careful evaluation of its progress, investment risks, and future market value [1] Group 1: Project Termination - The company will cease the clinical research and development of SY-009 to better allocate its R&D resources towards more advantageous projects in its pipeline [1] - The decision was influenced by various factors including project progress, development investment risks, and potential market value [1] Group 2: Financial Impact - The company will fully recognize an impairment provision for the capitalized R&D amount of the SY-009 project, which will reduce the total profit for the year 2025 by 55.7933 million yuan [1] - The impairment provision is based on the principle of accounting prudence and will be reflected in the company's 2025 annual report [1]